Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of BMS-986178 alone and with nivolumab and/or ipilimumab in advanced solid tumors
MOH_2017-10-15_000438Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of BMS-986178, nivolumab and ipilimumab in Nonhematologic neoplasms (6 arms), sponsored by Bristol Myers Squibb. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2017-10-15_000438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-15_000438.